MétaCan
Menu
Back to cohort

Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i>− MPN with de novo AML and with AML following MDS

2020· article· en· W3089665196 on OpenAlexaff
Vikas Gupta, Soyoung Kim, Zhen‐Huan Hu, Ying Liu, Mahmoud Aljurf, Ulrike Bacher, Amer Beitinjaneh, Jean‐Yves Cahn, Jan Černý, Edward A. Copelan, Shahinaz M. Gadalla, Robert Peter Gale, Siddhartha Ganguly, Biju George, Aaron T. Gerds, Usama Gergis, Betty K. Hamilton, Shahrukh K. Hashmi, Gerhard Hildebrandt, Rammurti T. Kamble, Tamila L. Kindwall‐Keller, Hillard M. Lazarus, Jane L. Liesveld, Mark R. Litzow, Richard T. Maziarz, Taiga Nishihori, Richard F. Olsson, David A. Rizzieri, Bipin N. Savani, Sachiko Seo, Melhem Solh, Jeff Szer, Leo F. Verdonck, Baldeep Wirk, Ann E. Woolfrey, Jean A. Yared, Edwin P. Alyea, Uday Popat, Ronald Sobecks, Bart L. Scott, Ryotaro Nakamura, Wael Saber

Bibliographic record

VenueBlood Advances · 2020
Typearticle
Languageen
FieldMedicine
TopicAcute Myeloid Leukemia Research
Canadian institutionsPrincess Margaret Cancer Centre
FundersJanssen PharmaceuticalsNational Institute of Allergy and Infectious DiseasesDaiichi Sankyo EuropeNational Cancer InstituteOffice of Naval ResearchLegend BiotechKite PharmaSanofi GenzymeTakeda OncologyHealth Resources and Services Administrationbluebird bioKiadis PharmaSwedish Orphan BiovitrumOmeros CorporationAstellas PharmaAdaptive BiotechnologiesPfizerIncyteAtara BiotherapeuticsActinium PharmaceuticalsNational Institutes of HealthRegeneron PharmaceuticalsMedical College of WisconsinJanssen BiotechHistoGeneticsU.S. Department of DefenseSanofiGlaxoSmithKlineU.S. NavyCelgeneCSL BehringBristol-Myers SquibbTerumo BCTAstraZenecaAstellas Pharma USBiomedical Advanced Research and Development AuthorityAmgenNational Heart, Lung, and Blood InstituteNovartis Pharmaceuticals CorporationMedacJazz PharmaceuticalsBe The Match Foundation
KeywordsHazard ratioInternal medicineMedicineMyeloid leukemiaOncologyMyelodysplastic syndromesProportional hazards modelTransplantationConfidence intervalMyeloidLeukemiaInternational Prognostic Scoring SystemGastroenterologyBone marrow

Abstract

fetched live from OpenAlex

Comparative outcomes of allogeneic hematopoietic cell transplantation (HCT) for BCR-ABL1- myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-MDS AML), are unknown. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared HCT outcomes in 177 MPN-BP patients with 4749 patients with de novo AML, and 1104 patients with post-MDS AML, using multivariate regression analysis in 2 separate comparisons. In a multivariate Cox model, no difference in overall survival (OS) or relapse was observed in patients with MPN-BP vs de novo AML with active leukemia at HCT. Patients with MPN-BP in remission had inferior OS in comparison with de novo AML in remission (hazard ratio [HR], 1.40 [95% confidence interval [CI], 1.12-1.76]) due to higher relapse rate (HR, 2.18 [95% CI, 1.69-2.80]). MPN-BP patients had inferior OS (HR, 1.19 [95% CI, 1.00-1.43]) and increased relapse (HR, 1.60 [95% CI, 1.31-1.96]) compared with post-MDS AML. Poor-risk cytogenetics were associated with increased relapse in both comparisons. Peripheral blood grafts were associated with decreased relapse in MPN-BP and post-MDS AML (HR, 0.70 [95% CI, 0.57-0.86]). Nonrelapse mortality (NRM) was similar between MPN-BP vs de novo AML, and MPN-BP vs post-MDS AML. Total-body irradiation-based myeloablative conditioning was associated with higher NRM in both comparisons. Survival of MPN-BP after HCT is inferior to de novo AML in remission and post-MDS AML due to increased relapse. Relapse-prevention strategies are required to optimize HCT outcomes in MPN-BP.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.794
Threshold uncertainty score0.473

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.029
GPT teacher head0.366
Teacher spread0.336 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations19
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueBlood AdvancesSame topicAcute Myeloid Leukemia ResearchFrench-language works237,207